Improved Adenoviral Vector for Vascular Gene Therapy : Beneficial Effects on Vascular Function and Inflammation.

HS Qian,K Channon,V Neplioueva,Q Wang,M Finer,L Tsui,SE George,J McArthur

DOI: https://doi.org/10.1161/hh0901.090926

IF: 23.213

2001-01-01

Circulation Research

Abstract:First-generation, El-deleted adenoviral vectors (Delta E1-AV) can transduce the vascular endothelium with high efficiency, but their use is limited by the resulting acute endothelial injury and the long-term development of intimal hyperplasia. To reduce the impact of viral proteins on the gene-modified cells, a second-generation adenoviral vector with an additional pair of deletions in the E4 region was developed. To determine whether this Delta E1/Delta E4-AV vector would be useful for vascular gene transfer, we directly compared the efficiency of gene transfer to uninjured rabbit carotid arteries using either an Delta E1/Delta E4-AV or an Delta E1-AV vector encoding beta -galactosidase. Both vectors efficiently transduced Vascular endothelium; however, the Delta E1/Delta E4-AV vector gene-modified vessels showed higher beta -galactosidase expression 10 days after gene transfer. Importantly, the Delta E1/Delta E4-AV vector produced substantially less endothelial cell activation, less inflammation, and reduced neointimal hyperplasia compared with the Delta E1-AV vector-treated vessels. The Delta E1-AV vector-transduced vessels also demonstrated significantly impaired endothelium-dependent relaxation whereas the Delta E1/Delta E4-AV vector did not impact vasomotor function, even at doses of virus in 5-fold excess of the amount required for > 90% transduction of the endothelium. We conclude that the Delta E1/Delta E4-AV vector is superior to the Delta E1-AV vector for vascular gene therapy because of the prolonged transgene expression, reduced vascular inflammation, reduced intimal hyperplasia, and maintenance of normal vasomotor function.